Identification of the molecular attributes required for aminoglycoside activity against Leishmania

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 33, 2013, Pages 13333-13338

  Shalev, Moran ^a   Kondo, Jiro ^b   Kopelyanskiy, Dmitry ^c   Jaffe, Charles L ^c   Adir, Noam ^a   Baasov, Timor ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b SOPHIA UNIVERSITY   (Japan)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Leishmania growth inhibition; Ribosomal decoding site; X ray analysis

Indexed keywords

ANTIBIOTIC G 418; APRAMYCIN; RIBOSOME RNA;

ANTILEISHMANIAL ACTIVITY; ARTICLE; BINDING SITE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG ACTIVITY; IN VITRO STUDY; LEISHMANIA; LEISHMANIASIS; MOLECULE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; RIBOSOME;

LEISHMANIA GROWTH INHIBITION; RIBOSOMAL DECODING SITE; X-RAY ANALYSIS;

CRYSTALLIZATION; GENTAMICINS; LEISHMANIA; LEISHMANIASIS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NEBRAMYCIN; PROTEIN BINDING; PROTEIN CONFORMATION; RIBOSOMAL PROTEINS;

EID: 84882336106     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1307365110     Document Type: Article

References (43)

1. Carter AP, et al. (2000) Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature 407(6802):340-348.
2. Ogle JM, et al. (2001) Recognition of cognate transfer RNA by the 30S ribosomal subunit. Science 292(5518):897-902.
3. Ogle JM, Murphy FV, Tarry MJ, Ramakrishnan V (2002) Selection of tRNA by the ribosome requires a transition from an open to a closed form. Cell 111(5):721-732.
4. Pape T, Wintermeyer W, Rodnina MV (2000) Conformational switch in the decoding region of 16S rRNA during aminoacyl-tRNA selection on the ribosome. Nat Struct Biol 7(2):104-107.
5. Bidou L, Allamand V, Rousset JP, Namy O (2012) Sense from nonsense: Therapies for premature stop codon diseases. Trends Mol Med 18(11):679-688.
6. Hainrichson M, Nudelman I, Baasov T (2008) Designer aminoglycosides: The race to develop improved antibiotics and compounds for the treatment of human genetic diseases. Org Biomol Chem 6(2):227-239.
7. Keeling KM, Wang D, Conard SE, Bedwell DM (2012) Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol 47(5):444-463.
8. Edlind TD (1989) Susceptibility of Giardia lamblia to aminoglycoside protein synthesis inhibitors: Correlation with rRNA structure. Antimicrob Agents Chemother 33(4): 484-488.
9. Hobbie SN, et al. (2011) Genetic reconstruction of protozoan rRNA decoding sites provides a rationale for paromomycin activity against Leishmania and Trypanosoma. PLoS Negl Trop Dis 5(5):e1161.
10. Kondo J, Koganei M, Maianti JP, Ly VL, Hanessian S (2013) Crystal structures of a bioactive 6′-hydroxy variant of sisomicin bound to the bacterial and protozoal ribosomal decoding sites. ChemMedChem 8(5):733-739.
11. Loebenberg D, Counels M, Waitz JA (1975) Antibiotic G418, a new micrommomosporaproduced aminglycoside with activity apainst protozoa and helminths: Antiparasitic activity. Antimicrob Agents Chemother 7(6):811-815.
12. Singh N, Kumar M, Singh RK (2012) Leishmaniasis: Current status of available drugs and new potential drug targets. Asian Pac J Trop Med 5(6):485-497.
13. Ben Salah A, et al. (2009) WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: A phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3(5):e432.
14. Ben Salah A, et al. (2013) Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N Engl J Med 368(6):524-532.
15. El-On J, Bazarsky E, Sneir R (2007) Leishmania major: In vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Exp Parasitol 116(2):156-162.
16. Davidson RN, den Boer M, Ritmeijer K (2009) Paromomycin. Trans R Soc Trop Med Hyg 103(7):653-660.
17. Sinha PK, et al. (2011) Phase 4 pharmacovigilance trial of paromomycin injection for the treatment of visceral leishmaniasis in India. J Trop Med 2011:645203.
18. Fernández MM, Malchiodi EL, Algranati ID (2011) Differential effects of paromomycin on ribosomes of Leishmania mexicana and mammalian cells. Antimicrob Agents Chemother 55(1):86-93.
19. Maarouf M, Lawrence F, Croft SL, Robert-Gero M (1995) Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol Res 81(5):421-425.
20. Kondo J (2012) A structural basis for the antibiotic resistance conferred by an A1408G mutation in 16S rRNA and for the antiprotozoal activity of aminoglycosides. Angew Chem Int Ed Engl 51(2):465-468.
21. Kondo J, François B, Urzhumtsev A, Westhof E (2006) Crystal structure of the Homo sapiens cytoplasmic ribosomal decoding site complexed with apramycin. Angew Chem Int Ed Engl 45(20):3310-3314.
22. Vicens Q, Westhof E (2001) Crystal structure of paromomycin docked into the eubacterial ribosomal decoding A site. Structure 9(8):647-658.
23. Vicens Q, Westhof E (2003) Crystal structure of geneticin bound to a bacterial 16S ribosomal RNA A site oligonucleotide. J Mol Biol 326(4):1175-1188.
24. François B, et al. (2005) Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: Role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res 33(17):5677-5690.
25. Kondo J, et al. (2007) Crystal structure of the bacterial ribosomal decoding site complexed with a synthetic doubly functionalized paromomycin derivative: A new specific binding mode to an a-minor motif enhances in vitro antibacterial activity. ChemMedChem 2(11):1631-1638.
26. Kondo J, et al. (2007) Differential selectivity of natural and synthetic aminoglycosides towards the eukaryotic and prokaryotic decoding A sites. ChemBioChem 8(14): 1700-1709.
27. Kondo J, Westhof E (2008) The bacterial and mitochondrial ribosomal A-site molecular switches possess different conformational substates. Nucleic Acids Res 36(8):2654-2666.
28. Kondo J, Urzhumtsev A, Westhof E (2006) Two conformational states in the crystal structure of the Homo sapiens cytoplasmic ribosomal decoding A site. Nucleic Acids Res 34(2):676-685.
29. Hermann T, Tereshko V, Skripkin E, Patel DJ (2007) Apramycin recognition by the human ribosomal decoding site. Blood Cells Mol Dis 38(3):193-198.
30. Pfister P, et al. (2005) Mutagenesis of 16S rRNA C1409-G1491 base-pair differentiates between 6'OH and 6'NH3+ aminoglycosides. J Mol Biol 346(2):467-475.
31. Nudelman I, et al. (2009) Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 52(9):2836-2845.
32. Pokrovskaya V, Belakhov V, Hainrichson M, Yaron S, Baasov T (2009) Design, synthesis, and evaluation of novel fluoroquinolone-aminoglycoside hybrid antibiotics. J Med Chem 52(8):2243-2254.
33. Nudelman I, et al. (2010) Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 18(11):3735-3746.
34. Matt T, et al. (2012) Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci USA 109(27):10984-10989.
35. Zufferey R, Bibis SS, Zhu T, Dhalladoo S (2012) Characterization of a compensatory mutant of Leishmania major that lacks ether lipids but exhibits normal growth, and G418 and hygromycin resistance. Exp Parasitol 130(3):200-204.
36. Jhingran A, Chawla B, Saxena S, Barrett MP, Madhubala R (2009) Paromomycin: Uptake and resistance in Leishmania donovani. Mol Biochem Parasitol 164(2):111-117.
37. Alvar J, et al.; WHO Leishmaniasis Control Team (2012) Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7(5):e35671.
38. Burke JF, Mogg AE (1985) Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 13(17):6265-6272.
39. Kandasamy J, et al. (2012) Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: A strategy for treatment of genetic diseases caused by nonsense mutations. J Med Chem 55(23):10630-10643.
40. Tsai A, et al. (2013) The impact of aminoglycosides on the dynamics of translation elongation. Cell Rep 3(2):497-508.
41. Han Q, et al. (2005) Molecular recognition by glycoside pseudo base pairs and triples in an apramycin-RNA complex. Angew Chem Int Ed Engl 44(18):2694-2700.
42. Francis SP, et al. (2013) A novel role of cytosolic protein synthesis inhibition in aminoglycoside ototoxicity. J Neurosci 33(7):3079-3093.
43. Shimony O, Jaffe CL (2008) Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods 75(2):196-200.